Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

2.19
+0.07003.30%
Post-market: 2.200.0097+0.44%19:48 EDT
Volume:1.06M
Turnover:2.35M
Market Cap:105.79M
PE:-1.43
High:2.27
Open:2.14
Low:2.13
Close:2.12
Loading ...

Cassava Sciences Q4 Operating Expenses USD 29.487 Million

THOMSON REUTERS
·
03 Mar

Cassava Sciences Q4 Basic EPS USD -0.57

THOMSON REUTERS
·
03 Mar

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

GlobeNewswire
·
03 Mar

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
28 Feb

Sector Update: Health Care Stocks Higher Thursday Afternoon

MT Newswires Live
·
28 Feb

Cassava Sciences Licenses Simufilam Patent From Yale University for Potential Treatment of Seizures; Shares Rise

MT Newswires Live
·
28 Feb

Cassava Sciences licenses simufilam method of treatment patent

TIPRANKS
·
27 Feb

Cassava Sciences Inc - Company to Pay Yale up to $4.5 Million in Milestones

THOMSON REUTERS
·
27 Feb

Cassava Sciences Inc - Enters License Agreement With Yale University

THOMSON REUTERS
·
27 Feb

Cassava Sciences Inc - Granted Exclusive Worldwide Rights to Yale's Patent Interests

THOMSON REUTERS
·
27 Feb

Cassava Sciences Licenses Simufilam Method of Treatment Patent

GlobeNewswire
·
27 Feb

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

Zacks
·
21 Feb

Clinical trials site shows Cassava Sciences REFOCUS-ALZ trial terminated

TIPRANKS
·
05 Feb

Cassava Sciences to Reduce Staff, Halt Further Analysis

MT Newswires Live
·
08 Jan

BRIEF-Cassava Sciences Provides A Business Update

Reuters
·
08 Jan

Cassava Sciences Inc: in Final Stages of Discontinuing Refocus-Alz Study

THOMSON REUTERS
·
08 Jan

Cassava Sciences Provides a Business Update

THOMSON REUTERS
·
08 Jan

Cassava- Topline Data From Phase 3 Refocus-Alz Study of Simufilam in Patients With Mild-to-Moderate Alzheimer's Disease Expected Late Q1/Early Q2 2025

THOMSON REUTERS
·
08 Jan

Cassava Sciences Inc: Implementing Cost Curtailment Including a Workforce Reduction of Approximately 33%

THOMSON REUTERS
·
08 Jan

Cassava Sciences Provides a Business Update

GlobeNewswire
·
08 Jan